[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355005-105":59,"doc-detail-355005-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","dual-targeting-of-brafv600e-and-ferroptosis-results-in-synergistic-anticancer-activity-via-iron-overload-and-enhanced-oxidative-stress","Dual targeting of BRAFV600E and ferroptosis results in synergistic anticancer activity via iron overload and enhanced oxidative stress","","Combination therapy targeting BRAFV600E-mutant cancers often faces relapse, resistance, and toxicity, motivating new approaches beyond BRAF/MEK inhibition. The study examines ferroptosis, an iron-dependent non-apoptotic cell death pathway, where BRAF inhibition can increase ferroptosis sensitivity via GPX4. Using in vitro, ex vivo, and in vivo ATC models, dual targeting promotes iron accumulation, oxidative stress, lipid peroxidation, and ferroptotic cell death, overcoming BRAF inhibitor resistance.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/dual-targeting-of-brafv600e-and-ferroptosis-results-in-synergistic-anticancer-activity-via-iron-overload-and-enhanced-oxidative-stress/355005/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/dual-targeting-of-brafv600e-and-ferroptosis-results-in-synergistic-anticancer-activity-via-iron-overload-and-enhanced-oxidative-stress/355005.png","ImageObject",300,407,{"name":92,"@type":93},"Ivy","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is dual targeting of BRAFV600E and ferroptosis being studied?","Question",{"text":112,"@type":113},"Because BRAF/MEK inhibitor responses are often not durable and resistance or toxicity is common in BRAFV600E-mutant cancers. The study investigates ferroptosis as a complementary vulnerability that can be enhanced by BRAF inhibition.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What models were used to test the combined therapy?",{"text":117,"@type":113},"The work evaluates anticancer activity in vitro, ex vivo, and in vivo using anaplastic thyroid cancer (ATC) models, including BRAFV600E-mutant cell lines and an orthotopic ATC mouse model.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the combination treatment cause synergistic anticancer effects?",{"text":121,"@type":113},"Combination therapy increases lipid peroxidation, reactive oxygen species, and intracellular Fe2+, while showing reduced ferroportin-1 expression, indicating enhanced iron accumulation and oxidative stress leading to increased ferroptotic cell death.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355005,1790194001,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","Hu etal. Journal of Experimental & Clinical Cancer Research (2026) 45:34 [https://doi.org/10.1186/s13046-025-03624-z](https://doi.org/10.1186/s13046-025-03624-z)  \nJournal of Experimental & Clinical Cancer Research  \nRESEARCH Open Access  \nDual targeting of BRAFV600E and ferroptosis results in synergistic anticancer activity via iron overload and enhanced oxidative stress  \nJiangnan Hu 1,2*, Chandrayee Ghosh 1, Tejinder P. Khaket 1, Zhongyue Yang 1, Yasmine Tabdili3, Eden D. Alamaw4, Myriem Boufraqech5, Scott J. Dixon6 and Electron Kebebew 1*  \nAbstract  \nBackground While combination BRAF and MEK inhibitor treatment in BRAFV600E-mutant cancers results in a response, treatment resistance and toxicity are common. Ferroptosis is an iron-dependent form of non-apoptotic cell death. BRAF inhibition has been associated with increased sensitivity to ferroptosis that is dependent on Glutathione Peroxidase 4 (GPX4) .  \nMethods In vitro, ex vivo, and in vivo models of anaplastic thyroid cancer (ATC) were used to evaluate the anticancer activity of combination BRAF inhibition and ferroptosis induction.  \nResults Targeting key regulators offerroptosis—GPX4, using RSL3 and ML162, and system Xc − , using erastin—induced significant cell death in all ATC cell lines. Combination of dabrafenib and RSL3 synergistically increased cell death in BRAFV600E-mutant ATC cells, and significantly inhibited colony formation. Mechanistically, lipid peroxidation, reactive oxygen species levels, and intracellular Fe2+ increased significantly with combination treatment compared with each agent alone. Analysis of cell membrane iron importers and exporters showed significantly lower expression of ferroportin-1 (an iron exporter), suggesting the synergistic anticancer activity was due to increased iron accumulation and oxidative stress, leading to enhanced ferroptotic cell death. BRAFV600E-mutant ATC cell spheroids showed synergistic cell death with dabrafenib and RSL3 treatment. In vivo, combination dabrafenib and ferroptosis induction (by targeting GPX4 using C18, and system Xc − with IKE) significantly inhibited tumor growth inan orthotopic ATC mouse model. Additionally, dabrafenib-resistant BRAFV600E-mutant ATC cells were more sensitive to ferroptosis induction than parental cells.  \nConclusions Dual targeting of BRAFV600E and ferroptosis results in synergistic anticancer activity and overcomes resistance to BRAF inhibition.  \nKeywords Anaplastic thyroid cancer, BRAF mutation, Ferroptosis, GPX4, Combination therapy  \n*Correspondence: Jiangnan Hu [johu@stanford.edu](johu@stanford.edu)[ ](johu@stanford.edu)Electron Kebebew [kebebew@stanford.edu](kebebew@stanford.edu)  \n1Department of Surgery, Stanford University, Stanford, CA, USA 2Department of Family Medicine, Michigan State University College of Human Medicine, East Lansing, MI, USA  \n3University of Arizona College of Medicine, Tucson, AZ, USA 4Department of Comparative Medicine, Stanford University, Palo Alto, CA, USA  \n5Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA  \n6Department of Biology, Stanford University, Stanford, CA, USA  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](","cbCaiqM9lSoUhGuL","https://ap.wps.com/l/cbCaiqM9lSoUhGuL","pdf",2837505,14,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Keywords","[{\"question\":\"Why is dual targeting of BRAFV600E and ferroptosis being studied?\",\"answer\":\"Because BRAF/MEK inhibitor responses are often not durable and resistance or toxicity is common in BRAFV600E-mutant cancers. The study investigates ferroptosis as a complementary vulnerability that can be enhanced by BRAF inhibition.\"},{\"question\":\"What models were used to test the combined therapy?\",\"answer\":\"The work evaluates anticancer activity in vitro, ex vivo, and in vivo using anaplastic thyroid cancer (ATC) models, including BRAFV600E-mutant cell lines and an orthotopic ATC mouse model.\"},{\"question\":\"How does the combination treatment cause synergistic anticancer effects?\",\"answer\":\"Combination therapy increases lipid peroxidation, reactive oxygen species, and intracellular Fe2+, while showing reduced ferroportin-1 expression, indicating enhanced iron accumulation and oxidative stress leading to increased ferroptotic cell death.\"}]","Dual targeting of BRAFV600E and ferroptosis results in synergistic anticancer activity via iron overload and enhanced oxidative stress | PDF",1790115340,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7eb19ed1ad36e398c2307de84b156e7e.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3087358ce86411aab8ff730176c8cc77.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/30b5bd4a25c93c4dcaa99be3b1d1f202.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c00ebceca2e30760c4650e0d1519c651.webp",980,1306]